Navigation Links
China Biologic Products Announces 2009 First Quarter Results Conference Call
Date:5/18/2009

TAI'AN CITY, Shandong, China, May 18 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that it will host a conference call at 8:00 a.m. EDT on Tuesday, May 19, 2009, to discuss the 2009 first quarter financial results.

Hosting the call will be Mr. Colin Zhao, Chief Executive Officer, and Mr. Tristan Kuo, Chief Financial Officer.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888- 419-5570. International callers should dial 617-896-9871. The pass code for the call is 634 701 69.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Tuesday, May 19, 2009 at 10:00 a.m. EDT. To access the replay, dial 888-286-8010, international callers should dial 617-801-6888. The conference pass code is 373 105 74.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's blood products are irreplaceable in the application of medical emergencies, and prevention and treatment for various diseases. It sells its plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     CFO
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office), or
     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... York, NY (PRWEB) , ... April 19, 2017 ... ... to combat Clostridium difficile (C. diff) infections through education and advocacy. Founded ... her life to a C. diff infection, the foundation has become the most-consulted ...
(Date:4/19/2017)... and PUNE, India , April 19, 2017 /PRNewswire/ ... "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the global ... $12,858 million by 2022, registering a CAGR of 9.6% from 2016 to 2022. ... ... ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 ... specialty finance firm that provides senior debt to ... the closing of a $20 million senior secured ... orthobiologics company engaged in the development and commercialization ... of orthopedic injuries. Cerapedics, lead product, ...
(Date:4/19/2017)...   Thermo Fisher Scientific Inc . today ... SEpsis (MOSES) Study have been published in the ... Medicine . Researchers from the study, titled "Serial ... From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study," ... assay to assess risk for 28 day all-cause ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):